

Novo, Anthropic Set Drug-Research Pact

BY ALEX JANIN
AND ADRIÀ CALATAYUD

Novo Nordisk, the Danish drugmaker behind blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, is working with Anthropic to use artificial intelligence for drug research.

Novo said Wednesday it would use Anthropic's science-specific platform, known as Claude Science, to help speed up the discovery and

development of new medicines and strengthen the pharmaceutical company's software development.

The partnership is the latest by a slate of drugmakers, including Eli Lilly, Merck and Roche, betting that AI can help them discover and produce medicines more quickly.

"AI can help us increase productivity in R&D and compress the path from research to marketed product. But be-

Please turn to page B2